Home › Allied-Bristol Life Sciences Licenses Platform Technology And Lead Molecules From Yale University
 

Keywords :   


Allied-Bristol Life Sciences Licenses Platform Technology And Lead Molecules From Yale University

2015-09-02 07:19:10| drugdiscoveryonline News Articles

Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned between Allied Minds and Bristol-Myers Squibb Company, announced that it has entered into a worldwide licensing agreement with Yale University for a proprietary platform technology and associated lead molecules that will be further developed to treat diseases such as prostate cancer, a leading cause of cancer-related deaths among American men

Tags: life technology university lead

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
24.05Post Office convictions to be quashed today as Vennells faces victims at inquiry
24.05April a washout for shops as sales slump
24.05'Joy' as Post Office convictions will be quashed
24.05Cannabis Laced Toothpaste
24.05Amorepacific-Hopkins NBRI Presents Skin Epigenetics Findings at SID
24.05Google to make Pixel phones and drones in India
24.05Eastern North Pacific Tropical Weather Outlook
24.05Atlantic Tropical Weather Outlook
More »